Dyskerin and cancer: More than telomerase. the defect in mRNA translation helps in explaining how a proliferative defect leads to cancer

Journal of Pathology

Volumn 222, Issue 4, 2010, Pages 345-349

  Montanaro, Lorenzo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

DKC1; Dyskerin; P53, p27; Telomerase; Translational control; X linked dyskeratosis congenita

Indexed keywords

DYSKERIN; MESSENGER RNA; TELOMERASE;

CANCER SUSCEPTIBILITY; CELL PROLIFERATION; DISEASE ASSOCIATION; DYSKERATOSIS CONGENITA; GENETIC CODE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RIBOSOME; RNA TRANSLATION; TUMOR SUPPRESSOR GENE;

CELL CYCLE PROTEINS; CELL PROLIFERATION; DYSKERATOSIS CONGENITA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER;

EID: 78349289939     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2777     Document Type: Review

References (51)

1. Knight SW, Vulliamy T, Forni GL, et al., Fine mapping of the dyskeratosis congenita locus in Xq28. J Med Genet 1996; 33: 993 - 995.
2. Heiss NS, Knight SW, Vulliamy TJ, et al., X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nature Genet 1998; 19: 32 - 38.
3. Zinesser F,. Atrophia cutis reticularis cum pigmentatione, dystrophia unguium et leukoplakia oris. Ikonogr Dermatol (Hyoto) 1906; 5: 219 - 223.
4. Engmann MF,. A unique case of reticular pigmentation of the skin with atrophy. Arch Dermatol Syphil 1926; 13: 685 - 687.
5. Cole HN, Rauschkolb JC, Toomey J,. Dyskeratosis congenita with pigmentation, dystrophia unguis and leukokeratosis oris. Arch Dermatol Syph 1930; 21: 71 - 95.
6. Knight S, Vulliamy T, Copplestone A, et al., Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol 1998; 103: 990 - 996.
7. Alter BP, Giri N, Savage SA, et al., Cancer in dyskeratosis congenita. Blood 2009; 113: 6549 - 6557.
8. Lafontaine DL, Bousquet-Antonelli C, Henry Y, et al., The box H + ACA snoRNAs carry Cbf5p, the putative rRNA pseudouridine synthase. Genes Dev 1998; 12: 527 - 537.
9. Ganot P, Bortolin ML, Kiss T,. Site-specific pseudouridine formation in preribosomal RNA is guided by small nucleolar RNAs. Cell 1997; 89: 799 - 809.
10. Kiss AM, Jády BE, Darzacq X, et al., Cajal body-specific pseudouridylation guide RNA is composed of two box H/ACA snoRNA-like domains. Nucleic Acids Res 2002; 30: 4643 - 4649.
11. Richard P, Darzacq X, Bertrand E, et al., A common sequence motif determines the Cajal body-specific localization of box H/ACA scaRNAs. EMBO J 2003; 22: 4283 - 4293.
12. Wang C, Meier UT,. Architecture and assembly of mammalian H/ACA small nucleolar and telomerase ribonucleoproteins. EMBO J 2004; 23: 1857 - 1867.
13. Mitchell JR, Wood E, Collins K,. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999; 402: 551 - 555.
14. Meier UT,. The many facets of H/ACA ribonucleoprotein. Chromosoma 2005; 114: 1 - 14.
15. Meier UT,. How a single protein complex accommodates many different H/ACA RNAs. Trends Biochem Sci 2006; 31: 311 - 315.
16. Giordano E, Peluso I, Senger S, et al., minifly, a Drosophila gene required for ribosome biogenesis. J Cell Biol 1999; 144: 1123 - 1133.
17. Ruggero D, Grisendi S, Piazza F, et al., Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003; 299: 259 - 262.
18. Mochizuki Y, He J, Kulkarni S, et al., Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl Acad Sci U S A 2004; 101: 10756 - 10761.
19. Kirwan M, Dokal I,. Dyskeratosis congenita, stem cells and telomeres. Biochim Biophys Acta 2009; 1792: 371 - 379.
20. Walne AJ, Marrone A, Dokal I,. Dyskeratosis congenita: a disorder of defective telomere maintenance? Int J Hematol 2005; 82: 184 - 189.
21. Ruggero D, Grisendi S, Piazza F, et al., Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003; 299: 259 - 262.
22. Ge J, Rudnick DA, He J, et al., Dyskerin ablation in mouse liver inhibits rRNA processing and cell division. Mol Cell Biol 2010; 30: 413 - 422.
23. Montanaro L, Chillà A, Trer D, et al., Increased mortality rate and not impaired ribosomal biogenesis is responsible for proliferative defect in dyskeratosis congenita cell lines. J Invest Dermatol 2002; 118: 193 - 198.
24. Wong JM, Collins K,. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev 2006; 20: 2848 - 2858.
25. Armanios M,. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 2009; 10: 45 - 61.
26. Walne AJ, Dokal I,. Advances in the understanding of dyskeratosis congenita. Br J Haematol 2009; 145: 164 - 172.
27. Drachtman RA, Alter BP,. Dyskeratosis congenita: clinical and genetic heterogeneity. Report of a new case and review of the literature. Am J Pediatr Hematol Oncol 1992; 14: 297 - 304.
28. Savage SA, Giri N, Baerlocher GM, et al., TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet. 2008; 82: 501 - 509.
29. Walne AJ, Vulliamy T, Beswick R, et al., TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 2008; 112: 3594 - 3600.
30. Montanaro L, Trere D, Derenzini M,. Nucleolus, ribosomes, and cancer. Am J Pathol 2008; 173: 301 - 310.
31. Derenzini M, Montanaro L, Chillà A, et al., Key role of the achievement of an appropriate ribosomal RNAcomplement for G1-S phase transition in H4-II-E-C3 rat hepatoma cells. J Cell Physiol 2005; 202: 483 - 491.
32. Chan SR, Blackburn EH,. Telomeres and telomerase. Philos Trans R Soc London B Biol Sci 2004; 359: 109 - 121.
33. Dokal I,. Dyskeratosis congenita in all its forms. Br J Haematol 2000; 110: 768 - 779.
34. Rudolph KL, Chang S, Lee HW, et al., Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701 - 712.
35. Baudin-Baillieu A, Fabret C, Liang XH, et al., Nucleotide modifications in three functionally important regions of the Saccharomyces cerevisiae ribosome affect translation accuracy. Nucleic Acids Res 2009; 37: 7665 - 7677.
36. Yoon A, Peng G, Brandenburger Y, et al., Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006; 312: 902 - 906.
37. Hellen CU, Sarnow P,. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev 2001; 15: 1593 - 1612.
38. Le Quesne JP, Spriggs KA, Bushell M, et al., Dysregulation of protein synthesis and disease. J Pathol 2010; 220: 140 - 151.
39. Hollstein M, Hainaut P,. Massively regulated genes: the example of TP53. J Pathol 2010; 220: 164 - 173.
40. Montanaro L, Calienni M, Bertoni S, et al., Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res 2010; 70: 4767 - 4777.
41. Bellodi C, Kopmar N, Ruggero D,. Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J 2010; 29: 1865 - 1876.
42. Liu Y, Elf SE, Miyata Y, et al., p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009; 4: 37 - 48.
43. Cheng T, Rodrigues N, Dombkowski D, et al., Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nature Med 2000; 6: 1235 - 1240.
44. Bellodi C, Krasnykh O, Haynes N, et al., Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res 2010; 70: 6026 - 6035.
45. Montanaro L, Brigotti M, Clohessy J, et al., Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J Pathol 2006; 210: 10 - 18.
46. Sieron P, Hader C, Hatina J, et al., DKC1 overexpression associated with prostate cancer progression. Br J Cancer 2009; 101: 1410 - 1416.
47. Derenzini M, Montanaro L, Treré D,. What the nucleolus says to a tumour pathologist. Histopathology 2009; 54: 753 - 762.
48. Treré D, Ceccarelli C, Montanaro L, et al., Nucleolar size and activity are related to pRb and p53 status in human breast cancer. J Histochem Cytochem 2004; 52: 1601 - 1607. (Pubitemid 39603258)
49. Poremba C, Heine B, Diallo R, et al., Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol 2002; 198: 181 - 189.
50. Kimura M, Koida T, Yanagita Y,. A study on telomerase activity and prognosis in breast cancer. Med Oncol 2003; 20: 117 - 126.
51. Montanaro L, Calienni M, Ceccarelli C, et al., Relationship between dyskerin expression and telomerase activity in human breast cancer. Cell Oncol 2008; 30: 483 - 490.